Consolidation with high-dose chemotherapy and stem cell support for responding patients with metastatic soft tissue sarcomas: prospective, single-institutional phase II study
Prognosis of patients with metastatic soft tissue sarcoma remains poor. Whether high-dose chemotherapy with stem cell support improves the long-term outcome for these patients is debatable. We present a prospective, single-institutional phase II study that enrolled 34 soft tissue sarcoma patients wi...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
23 November 2009
|
| In: |
Bone marrow transplantation
Year: 2010, Volume: 45, Issue: 7, Pages: 1234-1238 |
| ISSN: | 1476-5365 |
| DOI: | 10.1038/bmt.2009.333 |
| Online Access: | Resolving-System, lizenzpflichtig, Volltext: https://doi.org/10.1038/bmt.2009.333 Verlag, lizenzpflichtig, Volltext: https://www.nature.com/articles/bmt2009333 
|
| Author Notes: | B. Kasper, I. Scharrenbroich, T. Schmitt, P. Wuchter, S. Dietrich, A.D. Ho and G. Egerer |
| Summary: | Prognosis of patients with metastatic soft tissue sarcoma remains poor. Whether high-dose chemotherapy with stem cell support improves the long-term outcome for these patients is debatable. We present a prospective, single-institutional phase II study that enrolled 34 soft tissue sarcoma patients with advanced and/or metastatic disease. After four courses of chemotherapy consisting of doxorubicin and ifosfamide, responding patients in at least partial response (PR) were treated with high-dose chemotherapy (n=9); all other patients continued chemotherapy for two more cycles. After standard chemotherapy, PR (n=10), stable disease (SD, n=6) and progressive disease (PD, n=14) were attained for the evaluable patients. Twenty-nine patients died and five are alive with the disease. Median PFS was 11.6 months (range 8-15) for patients treated with high-dose chemotherapy (n=9) vs 5.6 months (range 0-19) for patients treated with standard chemotherapy. Median OS was 23.7 months (range 12-34) vs 10.8 months (range 0-39), respectively. The subgroup of patients treated with high-dose chemotherapy gained significant survival benefit. Nevertheless, high-dose chemotherapy as a possible consolidation strategy remains highly investigational. |
|---|---|
| Item Description: | Gesehen am 02.03.2023 |
| Physical Description: | Online Resource |
| ISSN: | 1476-5365 |
| DOI: | 10.1038/bmt.2009.333 |